Login / Signup

Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis.

Robert GilmorePatrick HilleyAshish SrinivasanMatthew ChoyPeter De Cruz
Published in: Journal of Crohn's & colitis (2021)
High-dose tofacitinib may have a role as salvage therapy in the setting of steroid-refractory ASUC. Prospective studies are required to determine the safety and efficacy of high-dose tofacitinib to determine whether it can be routinely recommended as primary or sequential salvage therapy in the setting of steroid-refractory ASUC.
Keyphrases
  • high dose
  • ulcerative colitis
  • rheumatoid arthritis
  • low dose
  • stem cell transplantation
  • stem cells
  • drug induced
  • mesenchymal stem cells
  • early onset
  • bone marrow
  • replacement therapy